FDA Requests Recall of Xiadafil VIP Tabs

The U.S. Food and Drug Administration today requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person's blood pressure and can cause other life-threatening side effects. These lots of Xiadafil VIP Tabs bear an expiration date of September 2009 (09/09). Xiadafil VIP Tabs are marketed as a dietary supplement for sexual enhancement and able to treat erectile dysfunction (ED).

Today's formal request follows an action  by the state of Florida to prevent the further distribution of this product into consumer channels.  FDA is advising consumers not to buy or use this product. The agency may take further regulatory action to protect consumers from this illegal product.